White & Case advises Berenberg on BioNTech’s public exchange offer for CureVac shares

Global law firm White & Case LLP has advised Joh. Berenberg, Gossler & Co. KG. (Berenberg) in connection with BioNTech SE's (BioNTech) public exchange offer for all outstanding shares in CureVac N.V. (CureVac).

Under the terms of the transaction, each CureVac share will be exchanged for approximately US$5.46 in BioNTech ADSs, resulting in an implied aggregate equity value for CureVac of approximately US$1.25 billion. Berenberg is acting as subscription agent for the public exchange offer.

The White & Case team in Frankfurt which advised on the transaction included partners Gernot Wagner, Yannick Adler and Alexander Kiefner, local partner Timo Lockemann and international attorney Zgjim Mikullovci.

Press contact
For more information please speak to your local media contact.